TrivarX Limited

OTCPK:MDBI.F Stock Report

Market Cap: US$16.7m

TrivarX Past Earnings Performance

Past criteria checks 0/6

TrivarX has been growing earnings at an average annual rate of 11.7%, while the Healthcare Services industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 0.4% per year.

Key information

11.73%

Earnings growth rate

33.28%

EPS growth rate

Healthcare Services Industry Growth1.72%
Revenue growth rate0.38%
Return on equity-7.46%
Net Margin-91.48%
Last Earnings Update30 Jun 2025

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How TrivarX makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:MDBI.F Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 251-110
31 Mar 252-110
31 Dec 242010
30 Sep 241-110
30 Jun 241-110
31 Mar 240-310
31 Dec 230-410
30 Sep 230-310
30 Jun 231-310
31 Mar 231-811
31 Dec 221-1211
30 Sep 221-1311
30 Jun 221-1311
31 Mar 221-711
31 Dec 211-110
30 Sep 211-110
30 Jun 211-110
31 Mar 211-210
31 Dec 201-210
30 Sep 201-310
30 Jun 201-420
31 Mar 201-420
31 Dec 191-521
30 Sep 193-631
30 Jun 194-750
31 Mar 193-1161
31 Dec 183-1582
30 Sep 183-1573
30 Jun 182-1673
31 Mar 183-1555
31 Dec 173-1346
30 Sep 173-1135
30 Jun 173-1024
31 Mar 173-923
31 Dec 164-712
30 Sep 163-712
30 Jun 162-612
31 Mar 162-611
31 Dec 151-700
30 Sep 151-700
30 Jun 150-800
31 Mar 150-500

Quality Earnings: MDBI.F is currently unprofitable.

Growing Profit Margin: MDBI.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MDBI.F is unprofitable, but has reduced losses over the past 5 years at a rate of 11.7% per year.

Accelerating Growth: Unable to compare MDBI.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDBI.F is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (20.3%).


Return on Equity

High ROE: MDBI.F has a negative Return on Equity (-7.46%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/25 19:44
End of Day Share Price 2026/01/06 00:00
Earnings2025/06/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TrivarX Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stuart RobertsPitt Street Research Pty Ltd.